세계의 희귀의약품 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Orphan Drugs Market is presumed to reach the market size of nearly USD 362.04 Billion by 2032 from USD 194.95 Billion in 2023 with a CAGR of 7.12% under the study period 2024 - 2032.

Orphan drugs are pharmaceutical medications created to treat rare diseases or conditions impacting a small number of individuals. Pharmaceutical companies often need to pay more attention to these diseases due to their limited patient populations and drug development and commercialization challenges. These drugs, including extended patent protection, tax credits, and accelerated approval processes, receive special regulatory incentives and market exclusivity to encourage their growth.

MARKET DYNAMICS

The increasing prevalence of rare diseases and disorders and advances in genetic research and diagnostic technologies drive the demand for orphan drugs targeting specific genetic mutations or rare conditions. Additionally, regulatory incentives and orphan drug designations granted by health authorities, such as the Orphan Drug Act in the United States and similar regulations in other countries, encourage pharmaceutical companies to invest in the research and development of orphan drugs. Furthermore, the growing patient advocacy and support groups for rare diseases are raising awareness and advocating for access to orphan drugs, driving demand and facilitating market growth. Moreover, advancements in biotechnology and drug development techniques, such as gene therapy, cell therapy, and precision medicine approaches, enable the development of innovative orphan drug therapies with improved efficacy and safety profiles.

Additionally, the increasing healthcare expenditure and insurance coverage for orphan drug treatments, combined with the growing acceptance of personalized medicine and value-based healthcare models, create favorable market conditions for orphan drug manufacturers. Furthermore, strategic collaborations and partnerships between pharmaceutical companies, academic institutions, and research organizations foster innovation and accelerate the development and commercialization of orphan drugs. However, increasing competition from alternative therapies and limited patient access may challenge the growth of the orphan drugs market in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of orphan drugs. The growth and trends of orphan drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the orphan drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Disease Type

• Oncology
• Gastrointestinal
• Pulmonary
• Neurology
• Hematology
• Cardiovascular
• Metabolic Disorders
• Endocrinology
• Infectious Diseases
• Others

By Indicator

• Biologic
• Non-Biologic

By Distribution Channel

• Hospital Pharmacies
• Specialty Pharmacies
• Retail Pharmacies
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Orphan Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Orphan Drugs market include Novartis AG, Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., Pfizer, Inc., Sanofi S.A., Alexion Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S, AstraZeneca plc, Eisai Co., Ltd., Daiichi Sankyo Company Limited, Bayer AG, GlaxoSmithKline plc, Merck & Co., Inc., Johnson & Johnson. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. ORPHAN DRUGS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Disease Type
  • 3.7.2 Market Attractiveness Analysis By Indicator
  • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ORPHAN DRUGS MARKET ANALYSIS BY DISEASE TYPE

• 5.1. Overview By Disease Type
• 5.2. Historical and Forecast Data
• 5.3. Analysis By Disease Type
• 5.4. Oncology Historic and Forecast Sales By Regions
• 5.5. Gastrointestinal Historic and Forecast Sales By Regions
• 5.6. Pulmonary Historic and Forecast Sales By Regions
• 5.7. Neurology Historic and Forecast Sales By Regions
• 5.8. Hematology Historic and Forecast Sales By Regions
• 5.9. Cardiovascular Historic and Forecast Sales By Regions
• 5.10. Metabolic Disorders Historic and Forecast Sales By Regions
• 5.11. Endocrinology Historic and Forecast Sales By Regions
• 5.12. Infectious Diseases Historic and Forecast Sales By Regions
• 5.13. Others Historic and Forecast Sales By Regions

6. GLOBAL ORPHAN DRUGS MARKET ANALYSIS BY INDICATOR

• 6.1. Overview By Indicator
• 6.2. Historical and Forecast Data
• 6.3. Analysis By Indicator
• 6.4. Biologic Historic and Forecast Sales By Regions
• 6.5. Non-biologic Historic and Forecast Sales By Regions

7. GLOBAL ORPHAN DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 7.1. Overview By Distribution Channel
• 7.2. Historical and Forecast Data
• 7.3. Analysis By Distribution Channel
• 7.4. Hospital Pharmacies Historic and Forecast Sales By Regions
• 7.5. Specialty Pharmacies Historic and Forecast Sales By Regions
• 7.6. Retail Pharmacies Historic and Forecast Sales By Regions
• 7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL ORPHAN DRUGS MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE ORPHAN DRUGS COMPANIES

• 9.1. Orphan Drugs Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF ORPHAN DRUGS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Novartis AG
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. Bristol-Myers Squibb Company
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. Celgene Corporation
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. F. Hoffmann-La Roche Ltd.
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. Pfizer Inc.
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. Sanofi S.A.
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. Alexion Pharmaceuticals Inc.
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. Eli Lilly And Company
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments
• 10.11. Novo Nordisk A/S
  • 10.11.1 Company Overview
  • 10.11.2 Company Revenue
  • 10.11.3 Products
  • 10.11.4 Recent Developments
• 10.12. AstraZeneca Plc
  • 10.12.1 Company Overview
  • 10.12.2 Company Revenue
  • 10.12.3 Products
  • 10.12.4 Recent Developments
• 10.13. Eisai Co. Ltd.
  • 10.13.1 Company Overview
  • 10.13.2 Company Revenue
  • 10.13.3 Products
  • 10.13.4 Recent Developments
• 10.14. Daiichi Sankyo Company Limited
  • 10.14.1 Company Overview
  • 10.14.2 Company Revenue
  • 10.14.3 Products
  • 10.14.4 Recent Developments
• 10.15. Bayer AG
  • 10.15.1 Company Overview
  • 10.15.2 Company Revenue
  • 10.15.3 Products
  • 10.15.4 Recent Developments
• 10.16. GlaxoSmithKline Plc
  • 10.16.1 Company Overview
  • 10.16.2 Company Revenue
  • 10.16.3 Products
  • 10.16.4 Recent Developments
• 10.17. Merck & Co. Inc.
  • 10.17.1 Company Overview
  • 10.17.2 Company Revenue
  • 10.17.3 Products
  • 10.17.4 Recent Developments
• 10.18. Johnson & Johnson
  • 10.18.1 Company Overview
  • 10.18.2 Company Revenue
  • 10.18.3 Products
  • 10.18.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies